Skip to content

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
  • Home
  • About
    • NIH Collaboratory
      • Coordinating Center
      • NIH Collaboratory Trials
      • Core Working Groups
      • Steering Committee
      • Distributed Research Network
      • Our Impact
    • Living Textbook
      • Table of Contents
      • How to Use This Site
  • Resources
    • Data and Resource Sharing
    • Training Resources
    • Tools for Researchers
    • Publications
    • Knowledge Repository
  • Webinar
  • Podcast
  • News
    • News Feed
    • Calendar
    • Subscribe
return to home
Subscribe to Newsletter go to twitter feed go to linkedin go to blue sky feed
Search
NIH Collaboratory
Living Textbook of
Pragmatic Clinical Trials

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
home button

Rethinking Clinical Trials

A Living Textbook of Pragmatic Clinical Trials

  • Design
    • What is a Pragmatic Clinical Trial?
    • Decentralized Pragmatic Clinical Trials
    • Developing a Compelling Grant Application
    • Experimental Designs and Randomization Schemes
    • Endpoints and Outcomes
    • Analysis Plan
    • Using Electronic Health Record Data
    • Building Partnerships and Teams to Ensure a Successful Trial
    • Intervention Delivery and Complexity
    • Patient Engagement
  • Data, Tools & Conduct
    • Assessing Feasibility
    • Acquiring Real-World Data
    • Assessing Fitness-for-Use of Real-World Data
    • Study Startup
    • Participant Recruitment
    • Monitoring Intervention Fidelity and Adaptations
    • Patient-Reported Outcomes
    • Clinical Decision Support
    • Mobile Health
    • Electronic Health Records–Based Phenotyping
    • Navigating the Unknown
  • Dissemination & Implementation
    • Data Sharing and Embedded Research
    • Dissemination Approaches for Different Audiences
    • Implementation
    • End-of-Trial Decision-Making
  • Ethics & Regulatory
    • Privacy Considerations
    • Identifying Those Engaged in Research
    • Collateral Findings
    • Consent, Disclosure, and Non-Disclosure
    • Data and Safety Monitoring
    • Ethical Considerations of Data Sharing in Pragmatic Clinical Trials
    • Ethics for AI and ML
    • IRB Responsibilities and Procedures

Non-disclosure of Research Activities – ARCHIVED

CHAPTER SECTIONS

Consent, Disclosure, and Non-Disclosure


Section 4

Non-disclosure of Research Activities – ARCHIVED

version 1.0 - removed 10/18/2022 go to latest version

Expand Contributors

Jeremy Sugarman, MD, MPH, MA
Kevin Weinfurt, PhD

Contributing Editor
Karen Staman, MS

Ethical Foundations and Requirements

Currently, the threshold for a determination is the same for both waiver and alteration of informed consent, which arguably limits the options of the IRB when determining what the consent process will be for a given study (McKinney et al 2015). Some have suggested that new standards are necessary to enable pragmatic research while ensuring the protection of patient’s rights and interests (McKinney et al 2015).

With non-disclosure (ie, if consent is waived), no attempt is made to notify or request permission for people whose information will be used or who may be affected by a trial.

Case Example: Lumbar Imaging With Reporting of Epidemiology (LIRE)

Lumbar Imaging With Reporting of Epidemiology (LIRE), an NIH Collaboratory Trial, was designed to test whether inserting epidemiological evidence (essentially representing the normal range) in lumbar spine imaging reports will reduce subsequent diagnostic and therapeutic interventions, including cross-sectional imaging (MR/CT), opioid prescriptions, spinal injections and surgery (Jarvik et al 2015). As part of their justification for a waiver of patient consent in the Project Summary, the investigators cite that the project is minimal risk and will not adversely affect the rights and welfare of the subjects, and that the research could not practicably carried out without a waiver [because there is no easily implementable means of obtaining consent and there is a large study population (~250,000)] AND:

“4.1.3c By informing primary care providers and patients of the study, we risk invalidating the results. If providers and patients are aware of the intervention but are allocated to the control group, they may nevertheless change their behavior.

4.1.3d The risk of contacting subjects is greater than the risk of the study procedures. The risk for breach of patient confidentiality increases when subject contact information is maintained for the purposes of contacting patients for their consent. It is our opinion that this increased risk far exceeds the risk to subjects associated with the insertion of epidemiologic data into the radiology report interpreted by their provider (Jarvik 2013).”

Individual Notification

Even when a waiver of consent is granted, some investigators provide individual notification and may offer an opportunity to opt out as a mechanism to preserve autonomy. For example, in the Time to Reduce End Stage Renal disease (TiME) trial (described in Section 3), all patients initiating treatment with maintenance hemodialysis at participating facilities were provided with written information that included the trial sponsor, the purpose of the trial, how the trial would affect dialysis session duration, the treating physician’s role, a description of the transmission of de-identified patient data to the University of Pennsylvania, a statement that no additional testing will be performed for the trial, and a toll-free telephone number to contact with questions or to opt-out of participation.

Previous Section Next Section

SECTIONS

CHAPTER SECTIONS

sections

  1. Introduction – ARCHIVED
  2. Informed Consent – ARCHIVED
  3. Alternative Approaches to Disclosure and Authorization – ARCHIVED
  4. Non-disclosure of Research Activities – ARCHIVED
  5. Data on Different Approaches to Disclosure – ARCHIVED

Resources

For more on non-disclosure, see the article Use of altered informed consent in pragmatic clinical research (McKinney et al. 2015).

REFERENCES

back to top

Jarvik JG. 2013. LIRE Supplementary Material.

Jarvik JG, Comstock BA, James KT, et al. 2015. Lumbar Imaging With Reporting of Epidemiology (LIRE): protocol for a pragmatic cluster randomized trial. Contemp Clin Trials. doi:10.1016/j.cct.2015.10.003. PMID: 26493088

McKinney RE, Beskow LM, Ford DE, et al. 2015. Use of altered informed consent in pragmatic clinical research. Clin Trials. 12:494–502. doi:10.1177/1740774515597688. PMID: 26374677.

back to top


Version History

July 3, 2020: Minor corrections to layout and formatting (changes made by D. Seils).

Published August 25, 2017

current section :

Non-disclosure of Research Activities – ARCHIVED

  1. Introduction – ARCHIVED
  2. Informed Consent – ARCHIVED
  3. Alternative Approaches to Disclosure and Authorization – ARCHIVED
  4. Non-disclosure of Research Activities – ARCHIVED
  5. Data on Different Approaches to Disclosure – ARCHIVED

Citation:

Weinfurt K, Sugarman J. Consent, Disclosure, and Non-Disclosure: Non-disclosure of Research Activities – ARCHIVED. In: Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials. Bethesda, MD: NIH Pragmatic Trials Collaboratory. Available at: https://rethinkingclinicaltrials.org/chapters/design/consent-disclosure-non-disclosure-top/non-disclosure-research-activities/. Updated July 9, 2025. DOI: 10.28929/024.

Footer Menu

  • How to Use This Site
  • About NIH Collaboratory
  • Enrollment Reporting
  • Grand Rounds
  • Funding Statement
Link to Twitter Link to LinkedIn Link to Blue Sky Link to NIH Collaboratory email

Reference in this Web site to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation by the U.S. Government or National Institutes of Health (NIH). NIH is not responsible for the contents of any “off-site” Web page referenced from this server.

Log in
Privacy Statement
WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly. Site Map